Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients

Cited by (205)

Items 101–200 of 205

1. Contribution of parasympathetic muscarinic augmentation of insulin secretion to olanzapine-induced hyperinsulinemia
   Michael Roehrhoff Rickels, Elys M. Perez, Amy J. Peleckis, Erica Al-Shehabi, Huong-Lan Nguyen, Darko Stefanovski, Karl Rickels, Karen L. Teff · 2018 · American Journal of Physiology-Endocrinology and Metabolism
2. Safety profile of clozapine: Analysis using national registry data in Japan
   Shinichi Imazu, Takeo Hata, Katsunori Toyoda, Yoichiro Kubo, Shigeru Yamauchi, Shinya Kinoshita, Masami Nishihara, Ken Inada, Tetsufumi Kanazawa · 2021 · Journal of Psychiatric Research
3. Pharmacological management of diabetes in severe mental illness: a comprehensive clinical review of efficacy, safety and tolerability
   John Lally, Aonghus O’ Loughlin, Brendon Stubbs, Allys Guérandel, Donal Brendan O'Shea, Fiona Gaughran · 2018 · Expert Review of Clinical Pharmacology
4. Association Between Antipsychotic Treatment and Advanced Diabetes Complications Among Schizophrenia Patients With Type 2 Diabetes Mellitus
   Chi‐Shin Wu, Susan Shur‐Fen Gau · 2015 · Schizophrenia Bulletin
5. Common mechanisms for type 2 diabetes and psychosis: Findings from a prospective birth cohort
   Benjamin Ian Perry, Hannah J Jones, Tom G. Richardson, Stanley Zammit, Nicholas J. Wareham, Glyn Lewis, Peter Brian Jones, Golam Mohammed Khandaker · 2020 · Schizophrenia Research
6. No differences in olanzapine‐ and risperidone‐related weight gain between women and men: a meta‐analysis of short‐ and middle‐term treatment
   Georgios Schoretsanitis, Marjan Drukker, Jim van Os, Koen R.J. Schruers, Maarten Bak · 2018 · Acta Psychiatrica Scandinavica
7. Metabolic syndrome in first‐time hospitalized patients with depression: a 1‐year follow‐up study
   Lene Nyboe, Claus Høstrup Vestergaard, Hans Lund, M. K. Møller, Poul Videbech · 2015 · Acta Psychiatrica Scandinavica
8. Body mass index and blood pressure in bipolar patients: Target cardiometabolic markers for clinical practice
   Alfredo B. Cuellar Barboza, Alejandra Cabello-Arreola, Stacey J. Winham, Colin L. Colby, Francisco Romo‐Nava, Nicolás A. Núñez, Robert J. Morgan, Ruchi Gupta, Joshua T. Bublitz, Miguel L. Prieto et al. · 2020 · Journal of Affective Disorders
9. Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia
   Mohammad M. Khan · 2016 · CNS Drugs
10. Clinical Application of Patient-Centered Diabetes Care for People With Serious Mental Illness
    Jay A. Hamm, Kelly D. Buck, Jasmine D. Gonzalvo · 2017 · Clinical Diabetes
11. Medication Continuity Among Medicaid Beneficiaries With Schizophrenia and Bipolar Disorder
    Jonathan D. Brown, Allison Barrett, Emily Caffery, Kerianne Hourihan, Henry T. Ireys · 2013 · Psychiatric Services
12. Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats
    Dejuan Li, Qin Yue, Lu Liu, Keke Che, Xuemei Liu, Changhua Hu · 2021 · Acta Pharmacologica Sinica
13. The second-generation antipsychotic drug aripiprazole modulates the serotonergic system in pancreatic islets and induces beta cell dysfunction in female mice
    Diana Grajales, Patricia Vázquez, Mónica Ruíz-Rosario, Eva Tudurí, Mercedes Mirasierra, Vítor Ferreira, Ana B. Hitos, Dóra Koller, Pablo Zubiaur, Juan C. Cigudosa et al. · 2021 · Diabetologia
14. Awareness of Pre-diabetes or Diabetes and Associated Factors in People With Psychosis
    Debra L. Foley, Andrew James Mackinnon, Vera Anne Morgan, Gerald Francis Watts, David Jonathan Castle, Anna J Waterreus, Cherrie Ann Galletly · 2016 · Schizophrenia Bulletin
15. Risk of New-Onset Diabetes After Long-Term Treatment With Clozapine in Comparison to Other Antipsychotics in Patients With Schizophrenia
    Peter F.J. Schulte, Johanna T.H. Bocxe, Hiëronymus J. Doodeman, Ingrid M.M. van Haelst, Dan Cohen · 2016 · Journal of Clinical Psychopharmacology
16. Assessing the risk of type 2 diabetes mellitus among children and adolescents with psychiatric disorders treated with atypical antipsychotics: a population-based nested case–control study
    Hankil Lee, D. Song, J. Kwon, E. Han, M. Chang, Hye-Young Kang · 2018 · European Child and Adolescent Psychiatry
17. Atypical antipsychotics and metabolic syndrome
    Abigail Perez Rodriguez, Kazuhiro Tajima-Pozo, Adrian Lewczuk, Francisco Montañés Rada · 2015 · Cardiovascular Endocrinology
18. Predicting type 2 diabetes prevalence for people with severe mental illness in a multi-ethnic East London population
    Diana D. Shamsutdinova, Jayati Das‐Munshi, Mark J. Ashworth, Angus Roberts, Daniel R. Stahl · 2023 · International Journal of Medical Informatics
19. Schizophrenia and the COVID-19 pandemic: A narrative review from the biomedical perspective
    Krzysztof Kowalski, Błażej Misiak · 2023 · Revista de Psiquiatría y Salud Mental
20. Cardiovascular risk factor associations in adults with psychosis and adults in a national comparator sample
    Debra L. Foley, Andrew James Mackinnon, Vera Anne Morgan, Gerald Francis Watts, Jonathan E. Shaw, Dianna J. Magliano, David Jonathan Castle, John Joseph McGrath, Anna J Waterreus, Cherrie Ann Galletly · 2015 · Australian & New Zealand Journal of Psychiatry
21. Association between polymorphisms of LEP, LEPR, DRD2, HTR2A and HTR2C genes and risperidone- or clozapine-induced hyperglycemia
    Apichaya Puangpetch, Pornpen Srisawasdi, Weerapon Unaharassamee, Napa Jiratjintana, Somlak Vanavanan, Suweejuk Punprasit, Chalitpon Na Nakorn, Chonlaphat Sukasem, Martin H. Kroll · 2019 · Pharmacogenomics and Personalized Medicine
22. Sex Differences in the Association of HOMA-IR Index and BDNF in Han Chinese Patients With Chronic Schizophrenia
    Yating Yang, Yulong Zhang, Juan Wang, Xiaoshuai Ning, Yelei Zhang, Tongtong Zhao, Yi Zhong, Zhiwei Liu, Lei Xia, Wenzheng Li et al. · 2021 · Frontiers in Psychiatry
23. Diabetes and early postpartum methicillin-resistant Staphylococcus aureus infection in US hospitals
    Andrea M. Parriott, Onyebuchi A. Arah · 2013 · American Journal of Infection Control
24. Life-threatening ketoacidosis in a pregnant woman with psychotic disorder
    Charlotte Frise, Ben Attwood, Peter Watkinson, Lucy H. Mackillop · 2015 · Obstetric Medicine
25. Quality of diabetes care in patients with schizophrenia: a case-control study in Qatar
    Mustafa Abdul Karim, Nadeen Al-Baz, Sami Ouanes, Ali Khalil, Ahmed Assar, Abdulkarim Alsiddiqi, Zeinab Dabbous, Mahmoud Ali Zirie, Peter W R Woodruff, Rayaz Ahmed Malik et al. · 2021 · BMC Psychiatry
26. The safety of atypical antipsychotics: does QTc provide all the answers?
    Jimmi Nielsen · 2011 · Expert Opinion on Drug Safety
27. Identifying determinants of diabetes risk and outcomes for people with severe mental illness: a mixed-methods study
    Jennie Lister, Lu Han, Sue Bellass, Jo Taylor, Sarah Louise Alderson, Tim Doran, Simon M. Gilbody, Catherine Elizabeth Hewitt, Richard I. G. Holt, Rowena Jacobs et al. · 2021 · Health Services and Delivery Research
28. The association between birth weight, ponderal index, psychotropic medication, and type 2 diabetes in individuals with severe mental illness
    Marie Kim Wium‐Andersen, Terese Sara Høj Jørgensen, Martin Balslev Jørgensen, Jørgen Rungby, Carsten Rygaard Hjorthøj, Holger Jelling Sørensen, Merete Osler · 2022 · Journal of Diabetes and its Complications
29. Algorithm‐based pharmacotherapy for first‐episode schizophrenia involuntarily hospitalized: A retrospective analysis of real‐world practice
    Bunta Yoshimura, Kojiro Sato, Manabu Takaki, Norihito Yamada · 2017 · Early Intervention in Psychiatry
30. Double jeopardy: diabetes and severe mental illness. Addressing the special needs of this vulnerable group
    Elizabeth Blanchard, Katherine Samaras · 2014 · Diabetes Management
31. Diabetes in late-life schizophrenia: Prevalence, factors, and association with clinical symptoms
    Lijuan Huo, Xiaobing Lu, Fengchun Wu, Xingbing Huang, Yuping Ning, Xiangyang Zhang · 2020 · Journal of Psychiatric Research
32. NHS Health Checks for people with mental ill-health 2013–2017: an observational study
    César Garriga, John P Robson, Carol A. C. Coupland, Julia Hippisley‐Cox · 2020 · Epidemiology and Psychiatric Sciences
33. Association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: A systematic review and meta-analysis
    Qi He, Peixin Zhu, Xi-Yan Liu, Chunyue Huo · 2024 · Schizophrenia Research
34. Attenuation of Olanzapine-Induced Endoplasmic Reticulum Stress Improves Insulin Secretion in Pancreatic Beta Cells
    Diana Grajales, Patricia Vázquez, Rosa Alén, Ana B. Hitos, Ángela M. Valverde · 2022 · Metabolites
35. Alterations in sorting and secretion of hepatic apoA5 induce hypertriglyceridemia due to short-term use of olanzapine
    Piaopiao Huang, Wenqiang Zhu, Jingmei Xiao, Yi-Qi Zhang, Rong Li, Yang Yang, Li Shen, Fei Luo, Wen Dai, Pingan Lian et al. · 2022 · Frontiers in Pharmacology
36. Unraveling the Mechanisms Underlying Olanzapine-Induced Insulin Resistance
    Nigel Irwin, Victor A. Gault · 2013 · Diabetes
37. Glucose homeostasis and cognitive functions in schizophrenia: a systematic review and meta-analysis
    Alexander Kancsev, Eszter Éva Virág-Tulassay, Marie Anne Engh, Szilvia Kiss‐Dala, András Horváth, Péter Hegyi, Szabolcs Kéri · 2025 · Scientific Reports
38. Real-world risk of diabetes with antipsychotic use in older New Zealanders: a case-crossover study
    Prasad S. Nishtala, Te‐yuan Chyou · 2016 · European Journal of Clinical Pharmacology
39. A pharmacist-managed cardiovascular risk-reduction clinic for individuals experiencing serious mental illness
    Jasmine D. Gonzalvo, Jay A. Hamm, Mu Shan · 2019 · Journal of the American Pharmacists Association
40. Meta-analysis of a family history of diabetes in schizophrenia
    Daley S. Morera, Brian J. Miller · 2023 · Schizophrenia Research
41. The Psychology of Food Cravings in Patients With First-Episode Psychosis
    Young-Hyuk Kim, Seunghyong Ryu, Nam Hee-Jung, Mina Kim, Min Jhon, Ju‐Yeon Lee, Jae‐Min Kim, Min Ho Shin, Young‐Chul Chung, Sung‐Wan Kim · 2020 · Frontiers in Psychiatry
42. The risk of diabetes and HbA1c deterioration during antipsychotic drug treatment: A Danish two‐cohort study among patients with first‐episode schizophrenia
    Nanna M. Madsen, Marc A. Sørensen, Andreas Aalkjær Danielsen, Mikkel Højlund, Christopher Rohde, Ole Köhler‐Forsberg · 2024 · Acta Psychiatrica Scandinavica
43. Association of antipsychotic drugs on type 2 diabetes mellitus risk in patients with schizophrenia: a population-based cohort and in vitro glucose homeostasis-related gene expression study
    Yi‐Jen Fang, Wan-Yi Lee, Cheng‐Li Lin, Y C Cheah, Hui‐Hsia Hsieh, Chi‐Hua Chen, Fuu‐Jen Tsai, Ni Tien, Yun-Ping Lim · 2024 · BMC Psychiatry
44. Public Stigma Toward Schizophrenia Within Latino Communities in the United States
    Robin E. Gearing, Kathryne B. Brewer, Micki Washburn, L. Christian Carr, Sean Burr, Katy Manning, Luis R. Torres · 2023 · Community Mental Health Journal
45. Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial
    Peng Xie, Tiannan Shao, Yujun Long, Weiwei Xie, Yangjun Liu, Ye Yang, Yuyan Huang, Renrong Wu, Qijian Deng, Hui Tang · 2024 · Lipids in Health and Disease
46. Simulated Effects of Policies to Reduce Diabetes Risk Among Adults With Schizophrenia Receiving Antipsychotics
    Andrew W. Mulcahy, Sharon‐Lise T. Normand, John W. Newcomer, Benjamin Colaiaco, Julie M. Donohue, Judith R. Lave, Emmett B. Keeler, Mark Sorbero, Marcela V. Horvitz-Lennon · 2017 · Psychiatric Services
47. Cardiometabolic Risk and Monitoring in Psychiatric Disorders
    Katherine Samaras · 2016 · Springer eBooks
48. Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment
    Gregory B. Kruse, Bruce J. O. Wong, Mei Sheng Duh, Patrick Lefèbvre, Marie‐Hélène Lafeuille, John M. Fastenau · 2015 · PharmacoEconomics
49. Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study
    Vasiliki Mamakou, Sophie Hackinger, Eleni Zengini, Evgenia I. Tsompanaki, Eirini Marouli, Ioannis Serafetinidis, Bram Peter Prins, Athina Karabela, Eirini Glezou, Lorraine Southam et al. · 2018 · BMC Psychiatry
50. Costo efectividad de los antipsicóticos en el tratamiento de mantenimiento de la esquizofrenia en Colombia
    Hoover Quitian, Jair A. Arciniegas, Adriana Patricia Bohórquez Peñaranda, Carlos Gómez–Restrepo · 2015 · Revista Colombiana de Psiquiatría
51. Tratamiento con antipsicóticos en la fase aguda del paciente adulto con diagnóstico de esquizofrenia
    Adriana Patricia Bohórquez Peñaranda, Carlos Gómez–Restrepo, Jenny García Valencia, Luis Eduardo Jaramillo González, Ana María de la Hoz Bradford, Álvaro Arenas, Nathalie Tamayo Martinez · 2014 · Revista Colombiana de Psiquiatría
52. Central registry in psychiatry: A structured review
    Jyoti Prakash, TS Ramakrishnan, RC Das, Kalpana Srivastava, Suresh Kumar Mehta, R Shashikumar · 2014 · Industrial Psychiatry Journal
53. Neurodevelopmental and Neuropsychiatric Disorders
    Akira Monji, Izumi Maezawa, Yoshito Mizoguchi, Takahiro A. Kato, Lee‐Way Jin · 2014 · Springer eBooks
54. Clozapine's Multiple Cellular Mechanisms: What Do We Know after More than Fifty Years? a Systematic Review and Critical Assessment of Translational Mechanisms Relevant for Innovative Strategies in Treatment-Resistant Schizophrenia
    Andrea de Bartolomeis, Licia Vellucci, Annarita Barone, Mirko Manchia, Vincenzo De Luca, Felice Iasevoli, Christoph Ulrich Correll · 2022 · SSRN Electronic Journal
55. Pharmaco-epidemiological description of the population of the Marche Region (central Italy) treated with the antipsychotic drug olanzapine.
    Fiorenzo Mignini, Maurizio Sabbatini, Chiara Pascucci, Fabio Petrelli, Iolanda Grappasonni, Nicola Vanacore · 2013 · PubMed
56. Profiling the Skeletal Muscle Proteome in Patients on Atypical Antipsychotics and Mood Stabilizers
    Kyle Jon Burghardt, Griffin Calme, Michael A. Caruso, Bradley H. Howlett, Elani Sanders, Zaher Msallaty, Abdullah Mallisho, Berhane Seyoum, Yue Andy Qi, Xiangmin Zhang et al. · 2022 · Brain Sciences
57. The 4th Schizophrenia International Research Society Conference, 5–9 April 2014, Florence, Italy: A summary of topics and trends
    Olukayode Abayomi, Davide Amato, C. C. Bailey, Byron K.Y. Bitanihirwe, Lynneice Bowen, Shimon Burshtein, Alexis E. Cullen, Montserrat Fusté, Ana Paula Herrmann, Babak Khodaie et al. · 2014 · Schizophrenia Research
58. Mental Health in People With Diabetes: A Needs Assessment for the Diabetes Educator
    Jasmine D. Gonzalvo, Mary de Groot, JOANNE K. RINKER, Andrea R. Hilligoss, Athena L. Vu · 2018 · AADE in Practice
59. Drug-induced hyperglycemia
    Ol'ga Dmitrievna Ostroumova, Акимова Елизавета Сергеевна, А. И. Кочетков · 2019 · Clinical pharmacology and therapy
60. Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs
    Jacob V. Spertus, Marcela V. Horvitz-Lennon, Sharon‐Lise T. Normand · 2019 · Medical Decision Making
61. Clinical Characterisation of the Co-Occurrence of Mental and Physical Disorders
    Richard I. G. Holt · 2025 · Springer eBooks
62. Diabetes and psychotic disorders 1 The epidemiology of diabetes in psychotic disorders
    Martha Coonfield Ward, Benjamin G. Druss · 2015
63. Metabolic dysfunction related to typical and atypical antipsychotics in drug-naive patients with nonaffective psychosis
    Tarek Asaad, Marwa Abd El Meguid, Marwa El Missiry, Rami Ali, Rasha E. Bassim, Sameh Taha · 2017 · Middle East Current Psychiatry
64. Clinical Factors Associated with New-Onset Glucose Intolerance among Patients with Schizophrenia during Clozapine Treatment: All-Case Surveillance in Japan
    Mikiko Ishibashi, Kentaro Matsui, M Kawano, Hidehiro Oshibuchi, Jun Ishigooka, Katsuji Nishimura, Ken Inada · 2020 · The Tohoku Journal of Experimental Medicine
65. Significance and Factors Associated with Antipsychotic Polypharmacy Utilization Among Publicly Insured US Adults
    Marcela V. Horvitz-Lennon, Rita Volya, Katya Zelevinsky, Mimi Shen, Julie M. Donohue, Andrew W. Mulcahy, Sharon‐Lise T. Normand · 2021 · Administration and Policy in Mental Health and Mental Health Services Research
66. Use of antidepressant medications not associated with A1C among individuals with diabetes in NHANES sample
    Jamie Kammer, Akiko S. Hosler, Emily Leckman‐Westin, Albert Gregory DiRienzo · 2016 · Primary care diabetes
67. Multiple indicators of ill health are evident in people with psychosis
    Debra L. Foley · 2017 · Evidence-Based Mental Health
68. Incentives to Reduce Metabolic Side Effects of Antipsychotics: Reply
    Christina V. Mangurian, Susan M. Essock, Lloyd I. Sederer · 2011 · Psychiatric Services
69. Antipsychotics and Medical Comorbidity: A Retrospective Study in an Urban Outpatient Psychiatry Clinic
    Catherine W. Bennett, Lauren Gensler, David R. Goldsmith · 2022 · Community Mental Health Journal
70. Research on comorbidity characteristics and patterns of hospitalized participants with schizophrenia in China
    Xinru Huang, Ting Zhang, Bin Li, Yahui Meng, Fen Li · 2025 · Frontiers in Psychiatry
71. Risk of diabetes mellitus with olanzapine compared to clozapine: A systematic review and meta‐analysis
    Keigo Onda, Rizal Ichwansyah, Shuken Boku · 2025 · Psychiatry and Clinical Neurosciences Reports
72. The Impact of Air Pollution and Obesity on Cognitive Decline and Risk of Alzheimer’s Disease
    Zoe A. Keller, Katherine M. Eggers, Joshua P. Nixon, Tammy A. Butterick · 2025 · International Journal of Molecular Sciences
73. Aripiprazol: farmacología, eficacia clínica, seguridad y tolerabilidad en el adulto.
    Francisco Javier Domínguez Belloso, Antonio Soto Loza · 2011 · Psiquiatria.com
74. Changes in weight and metabolic parameters following long-term iloperidone use: A meta-analysis of data from 9 Phase II and III trials of iloperidone
    Marla Hochfeld, Saeeduddin Ahmed, Xiangyi Meng, Adam Winseck · 2012 · Open Journal of Psychiatry
75. Mind the mortality gap: the importance of metabolic function in mental illnesses
    Oliver David Howes, Katherine Beck · 2013 · Psychopharmacology
76. Diabetogenic Effects Associated with Psychiatric Treatment
    Vasiliki Mamakou, Ioanna Eleftheriadou, Anastasios Tentolouris, Nikolaos Sabanis, Aikaterini Drylli, Nikolaοs Tentolouris · 2018 · Current Pharmacology Reports
77. Evaluación y seguimiento metabólico del paciente con diagnóstico de esquizofrenia
    Gabriel Fernando Oviedo Lugo, Carlos Gómez–Restrepo, Adriana Patricia Bohórquez Peñaranda, Jenny García Valencia, Luís Eduardo Jaramillo, Nathalie Tamayo, María Luisa Carrero Núñez de Arenas, Carolina Vélez Fernández · 2015 · Revista Colombiana de Psiquiatría
78. Efectos adversos metabólicos y endocrinos de los antipsicóticos de segunda generación en niños y adolescentes: una revisión sistemática de ensayos aleatorizados, controlados con placebo y guías de práctica clínica
    M.A.F. De Hert, Marie Dobbelaere, E.M. Sheridan, Dan Cohen, Christoph Ulrich Correll · 2011 · Psiquiatría Biológica
79. Anti-Psychotic Medication and the Pattern of Cardiovascular Risk Factors: A Population Based Study (The Ayrshire Diabetes Follow-Up Cohort (ADOC) Study)
    Lee Euan Sit, Mario D. Hair, Lyall Cameron, Andrew Collier, Ammar Abdeen, Karthigayan Kessavalou · 2017 · Journal of Addiction Research & Therapy
80. Metabolic Side Effects of Antipsychotic Medication: An Overview
    Jung Sun Lee · 2019 · 신경정신의학
81. EFFECT OF VITAMIN D SUPPLEMENTATION ON ORAL GLUCOSE TOLERANCE IN INDIVIDUALS AT RISK FOR DEVELOPING TYPE 2 DIABETES
    Tracy Moreira‐Lucas · 2018 · TSpace (University of Toronto)
82. Reply
    Jimmi Nielsen, David M. Taylor · 2011 · Acta Psychiatrica Scandinavica
83. Schwere psychische Erkrankungen und Diabetes mellitus Typ-2
    De Hert, Marc, Johan Detraux, Davy Vancampfort, Correll, Chistopher · 2012 · Lirias
84. L'association clozapine avec un autre antipsychotique dans le traitement de la schizophrénie hyper-résistante : analyse des pratiques de prescription au travers d'une étude observationnelle
    Antoine Barlatier · 2014 · HAL
85. Schizophrenia and Medical Illness: Is Medical Illness the Consequence of Schizophrenia or Its Treatment?
    Jimmi Nielsen · 2011 · Springer eBooks
86. Design, Synthesis, and Pharmacological Evaluation of Novel Antipsychotic Drugs Based on Olanzapine That Display Reduced Weight Gain and Metabolic Side Effects
    Somayeh Jafari · 2012 · Research Online (University of Wollongong)
87. Cardiovascular disease and schizophrenia: do we know enough?
    Richard Eric Hodgson, Hiram Joseph Wildgust, Michael Beary · 2013 · The Psychiatrist
88. A Misused Term
    Harold A. Maio · 2011 · Psychiatric Services
89. Microglial Abnormalities in the Pathophysiology of
    Schizophrenia Monji, Yoshito Mizoguchi, Takahiro A. Kato · 2014
90. MedicationContinuityAmong MedicaidBeneficiariesWith SchizophreniaandBipolarDisorder
    Jonathan D. Brown, Kerianne Hourihan, Henry T. Ireys · 2013
91. Antipsychotics: A General View of Therapeutic and Adverse Effects
    2013 · WORLD SCIENTIFIC eBooks
92. World Psychiatryis indexed in PubMed, Current Contents/Clinical Medicine, Current Contents/Social and Behavioral Sciences, Science Citation Index, and EMBASE Âñåìèðíàÿ Ïñèõèàòðè÷åñêàÿ Àññîöèàöèÿ (ÂÏÀ)
    Mario Maj, Èçáðàííûé Ïðåçèäåíò, Allan Tasman, Helen Herrman · 2011
93. Quelle modalité de traitement médicamenteux ?
    B. Giordana · 2019 · Elsevier eBooks
94. Antipsychotics and Cardiac Side Effects
    Annamaria Mascolo, Cristina Scavone, Concetta Rafaniello, Annalisa Capuano · 2019 · Springer eBooks
95. The Relative Risk of Developing Type 2 Diabetes Mellitus in Young Adults with Schizophrenia Treated with Different Atypical Antipsychotic
    Nicolae-Marius Cason, Petru Aurel Babeș, Enikő Béres, Katalin Babeș · 2019 · Romanian Journal of Diabetes Nutrition and Metabolic Diseases
96. Diabetes Mellitus akibat Anti Psikotik pada Pasien Skizofrenia
    Danang hafizfadillah, Rasmi Zakiah Oktarlina · 2021 · Medical Profession Journal of Lampung
97. The Last Word: Beyond Toleration
    Edward W. James · 1985 · Journal of international women's studies
98. Antipsychotic drugs
    Alfonso Carvajal, Luis H. Martín Arias · 2012 · Side effects of drugs annual
99. Antipsychotics and Cardiac Side Effects
    Annamaria Mascolo, Cristina Scavone, Concetta Rafaniello, Annalisa Capuano · 2020 · Springer eBooks
100. METABOLIC SYNDROME IN PATIENTS WITH PSYCHOSIS USING SECOND-GENERATION ANTIPSYCHOTICS
     SarathChandra Ivaturi, Sri Ramya, Syed Zainab · 2022 · PARIPEX-INDIAN JOURNAL OF RESEARCH